Prof Michael Ehrenstein

Prof Michael EhrensteinTel: 020 3447 9035
Fax: 020 3447 9278

University College Hospital


Professional background

Professor Michael Ehrenstein is a Consultant Rheumatologist at UCL Hospitals. His key interests are in new therapies for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and other autoimmune rheumatic diseases. He leads the New Therapies Clinic for inflammatory arthritis at UCL Hospitals and has established with colleagues the Early Arthritis Clinic to enable rapid access for patients with rheumatoid arthritis. Michael studied medicine at The Middlesex Hospital, and trained in Rheumatology at The Hammersmith Hospital and Addenbrooke’s Hospital, Cambridge. He was previously MRC Clinician Scientist at Cambridge University.  He was awarded a PhD at UCL on the pathogenesis of autoimmune rheumatic disease. He is a member of NHS England’s Clinical Reference Group for Specialist Rheumatology. He represents rheumatology at the Use of Medicines Committee at UCLH. He has undertaken many roles for Arthritis Research UK including as Senior Clinical Advisor, for The British Society for Rheumatology, and advised licensing authorities (MHRA) regarding new therapies for arthritis.

Research interests

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Systemic lupus erythematosus


1. Ellis, S.D., J.L. McGovern, A. van Maurik, D. Howe, M.R. Ehrenstein*, and C.A. Notley. 2014. Induced CD8 FOXP3 regulatory T cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane TNF-alpha and CD86. Arthritis Rheumatol 66:2694-705

2. Rapetti, L., K.M. Chavele, C.M. Evans, and M.R. Ehrenstein. 2013. B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis. Ann Rheum Dis Nov 18.

3. Carter, L.M., D.A. Isenberg, and M.R. Ehrenstein. 2013. Elevated Serum BAFF Levels Are Associated With Rising Anti-Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus. Arthritis Rheum 65:2672-2679.

4. McGovern, J., D. Nguyen, N. D.A, C. Mauri, D.A. Isenberg, and M.R. Ehrenstein. 2012. Th17 cells are restrained by regulatory T cells from patients responding to anti-TNF antibody therapy via inhibition of IL-6. Arthritis Rheum 64:3129-3138.

5. Flores-Borja, F., E.C. Jury, C. Mauri, and M.R. Ehrenstein. 2008. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A 105:19396-19401.

6. Nadkarni, S., C. Mauri, and M.R. Ehrenstein. 2007. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33-39.

7. Pan-Hammarstrom, Q., A.M. Jones, A. Lahdesmaki, W. Zhou, R.A. Gatti, L. Hammarstrom, A.R. Gennery, and M.R. Ehrenstein. 2005. Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med 201:189-194. Impact Factor 13.

8. Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277-285.

9. Leandro, M.J., J.C. Edwards, G. Cambridge, M.R. Ehrenstein, and D.A. Isenberg. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673-2677.

10. Ehrenstein, M.R., H.T. Cook, and M.S. Neuberger. 2000. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 191:1253-1258.

GMC/GDC number: 3260874